Key result
MYH7 variation in HCM links to ~70% higher incident AF risk vs other sarcomeric genes.
Why the study?
The relationship between genetic variation and incident atrial fibrillation in hypertrophic cardiomyopathy patients has been poorly defined.
Does MYH7 sarcomeric gene variation increase the risk of incident atrial fibrillation in adult hypertrophic cardiomyopathy patients compared to other sarcomeric gene variations?
Cohort (n=1,040)
Yes
Does MYH7 sarcomeric gene variation increase the risk of incident atrial fibrillation in adult hypertrophic cardiomyopathy patients compared to other sarcomeric gene variations?
Hazard Ratio: 1.7 (95% CI 1.1–2.6)
p-value: p=0.009
In adult patients with hypertrophic cardiomyopathy, MYH7 sarcomeric gene variation is associated with a 1.7-fold higher risk of incident atrial fibrillation compared to other sarcomeric gene variations.
May support intensified AF surveillance in MYH7 HCM; extends genotype-phenotype data but leaves open prospective validation.
Background Although atrial fibrillation (AF) is common in hypertrophic cardiomyopathy (HCM) patients, the relationship between genetic variation and AF has been poorly defined. Characterizing genetic subtypes of HCM and their associations with AF may help to improve personalized medical care. We aimed to investigate the link between sarcomeric gene variation and incident AF in HCM patients. Methods and Results Patients from the multinational Sarcomeric Human Cardiomyopathy Registry were followed for incident AF. Those with likely pathogenic or pathogenic variants in sarcomeric genes were included. The AF incidence was ascertained by review of medical records and electrocardiograms at each investigative site. One thousand forty adult HCM patients, without baseline AF and with likely pathogenic or pathogenic variation in either MYH7 (n=296), MYBPC3 (n=659), or thin filament genes (n=85), were included. Compared with patients with variation in other sarcomeric genes, those with MYH7 variants were younger on first clinical encounter at the Sarcomeric Human Cardiomyopathy Registry site and more likely to be probands than the MYBPC3 variants. During an average follow-up of 7.2 years, 198 incident AF events occurred. Patients with likely pathogenic or pathogenic mutations in MYH7 had the highest incidence of AF after adjusting for age, sex, proband status, left atrial size, maximal wall thickness, and peak pressure gradient (hazard ratio, 1.7; 95% CI, 1.1-2.6; P=0.009). Conclusions During a mean follow-up of 7.2 years, new-onset AF developed in 19% of HCM patients with sarcomeric mutations. Compared with other sarcomeric genes, patients with likely pathogenic or pathogenic variation in MYH7 had a higher rate of incident AF independent of clinical and echocardiographic factors.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2018) conducted a cohort in Hypertrophic cardiomyopathy (n=1,040). MYH7 sarcomeric gene variation vs. Variation in other sarcomeric genes (MYBPC3 or thin filament genes) was evaluated on Incident atrial fibrillation (HR 1.7, 95% CI 1.1-2.6, p=0.009). Compared with other sarcomeric genes, MYH7 gene variation in hypertrophic cardiomyopathy patients was associated with a higher risk of incident atrial fibrillation (HR 1.7; 95% CI 1.1-2.6; P=0.009).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: